|
On (b)(4) 2018, immucor tested gamma-clone anti-s lot 625014 with selected cells from panocell-20 lot 44367.Four s positive and 4 s negative cells were selected.All cells resulted as expected.Controls and retention product performed as expected.On (b)(4)2018, immucor tested gamma-clone anti-s lot 625014 with the returned sample (b)(6).Controls performed as expected and the returned sample resulted negative.On (b)(4) 2018 immucor notified the customer of the following that: "we received sample for investigation.We tested our retention product and your returned sample.The following is a summary of our product investigation laboratory's findings.We tested the returned sample (b)(6) with retention anti-s lot 625014.Controls performed as expected and the returned sample resulted negative.We reproduced your report.The sample submitted is from a patient with sickle cell disease and most likely from african-american decent.Dna information you supplied does not state if the s antigen presents as a variant form of normal s antigens.Therefore by serology, this s antigen may or may not react with some examples of commercial anti-s antisera due to different clones where the antisera are derived.Immucor anti-s monoclonal gammaclone is manufactured from a different clone than bio-rad anti-s.This could account for the unexpected reactivity you observed.Our investigation did not identify a product deficiency, retention products performed as expected." the internal immucor document number for this report is (b)(4).
|